Neutralizing antibodies to ebola virus glycoprotein and their use

US11976109B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Nancy Sullivan · Kensington, US
• Kendra Leigh · Frankfurt am Main, DE
• John Misasi · Kensington, US
• Alberto Cagigi · Stockholm, SE

Key dates

• Filing date: Dec 31, 2018
• Grant date: May 7, 2024
• Expiry date: Jun 10, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2469/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and antigen binding fragments that specifically bind to ebolavirus glycoprotein and neutralize ebolavirus infection are disclosed. Nucleic acids encoding these antibodies, vectors, and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an ebolavirus infection in a subject.